India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Sansera Engineering: An Aerospace and Semiconductor Play

ESDS Software IPO: India's First Data Centre Company Going Public

Lumino Industries IPO Review: Wire & Cables Manufacturing + EPC Play

DMart Ready: The "Anti-Quick Commerce" Retail

Sona Comster 2.0: Not an Usual Auto Ancillary Company

Usha Martin: Value-Added Products Start Driving the Next Leg of Growth

Wendt India: A Precision Grinding Solution Provider Making Turnaround

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Solara Active Pharma Sciences / Equity Bottom-Up

Solara Active Pharma Sciences (SOLARA IN)

<ul>
<li>Solara's Q1 FY27 consolidated net profit rose 55% YoY to INR 16.3 crore on 19.5% revenue growth, its strongest quarterly EBITDA in 18 quarters.</li>
<li>Debt has fallen sharply on rights-issue proceeds and a CRISIL rating upgrade, just as management weighs strategic options, including a possible sale, for the loss-making Ibuprofen business.</li>
<li>How the base API and CRAMS franchise's structural margin recovery could change Solara's earnings trajectory through FY27, and where the risks still sit.</li>
</ul>


Solara's Q1 FY27 consolidated net profit rose 55% YoY to INR 16.3 crore on 19.5% revenue growth, its strongest quarterly EBITDA in 18 quarters.
Debt has fallen sharply on rights-issue proceeds and a CRISIL rating upgrade, just as management weighs strategic options, including a possible sale, for the loss-making Ibuprofen business.
How the base API and CRAMS franchise's structural margin recovery could change Solara's earnings trajectory through FY27, and where the risks still sit.


Solara Active Pharma: Carving Out Ibuprofen to Recapture Margin